Journal of Clinical Oncology, Vol 15, 1071-1079, Copyright © 1997 by American Society of Clinical Oncology

ARTICLES

Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors

LC Pronk, JH Schellens, AS Planting, MJ van den Bent, PH Hilkens, ME van der Burg, M de Boer-Dennert, J Ma, C Blanc, M Harteveld, R Bruno, G Stoter and J Verweij
Department of Medical Oncology and Neuro-Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, the Netherlands.

PURPOSE: This phase I study was performed to assess the feasibility of the combination of docetaxel and cisplatin and to determine the maximum- tolerated dose (MTD) and the side effects with an emphasis on sequence- dependent side effects. MATERIALS AND METHODS: Patients who were not pretreated with taxanes or cisplatin derivatives and who had received no more than one prior combination chemotherapy regimen or two single- agent regimens were entered. Treatment consisted of docetaxel given as a 1-hour infusion followed by cisplatin as a 3-hour infusion (schedule A), or cisplatin followed by docetaxel (schedule B). Docetaxel doses ranged from 55 to 100 mg/m2 and cisplatin doses from 50 to 100 mg/m2. RESULTS: Leukocytopenia and granulocytopenia were common (overall, 90%; grade 3 or 4, 87%), short-lasting, and docetaxel dose-dependent. Infections and neutropenic fever occurred in 10% and 4.5% of courses, respectively. Nonhematologic toxicities were mild to moderate and included alopecia, nausea, vomiting, diarrhea, mucositis, neurotoxicity, fluid retention, and skin and nail toxicity. There were no significant differences in pharmacokinetic parameters between schedules A and B. Tumor responses included one complete response (CR) and nine partial responses (PRs). CONCLUSION: The dose levels docetaxel 100 mg/m2 plus cisplatin 75 mg/m2 and docetaxel 85 mg/m2 plus cisplatin 100 mg/m2 appeared to be manageable. At these dose levels, the median relative dose-intensity was high and 81% and 88% of all cycles, respectively, could be given at full dose. Schedule A is advocated for further treatment.

This article has been cited by other articles:

				M. S H Lam and R. J Ignoffo A guide to clinically relevant drug interactions in oncology Journal of Oncology Pharmacy Practice, June 1, 2003; 9(2-3): 45 - 85. [Abstract] [PDF]

				A. M. Minisini, A. Tosti, A. F. Sobrero, M. Mansutti, B. M. Piraccini, C. Sacco, and F. Puglisi Taxane-induced nail changes: incidence, clinical presentation and outcome Ann. Onc., February 1, 2003; 14(2): 333 - 337. [Abstract] [Full Text] [PDF]

				F. E. de Jongh, J. Verweij, W. J. Loos, R. de Wit, M. J.A. de Jonge, A. S.T. Planting, K. Nooter, G. Stoter, and A. Sparreboom Body-Surface Area-Based Dosing Does Not Increase Accuracy of Predicting Cisplatin Exposure J. Clin. Oncol., September 1, 2001; 19(17): 3733 - 3739. [Abstract] [Full Text] [PDF]

				K. Itoh, Y. Sasaki, H. Fujii, H. Minami, T. Ohtsu, H. Wakita, T. Igarashi, Y. Watanabe, Y. Onozawa, M. Kashimura, et al. Study of Dose Escalation and Sequence Switching of Administration of the Combination of Docetaxel and Doxorubicin in Advanced Breast Cancer Clin. Cancer Res., October 1, 2000; 6(10): 4082 - 4090. [Abstract] [Full Text]

				C. P. Belani Paclitaxel and Docetaxel Combinations in Non-Small Cell Lung Cancer Chest, April 1, 2000; 117(4_suppl_1): 144S - 151S. [Abstract] [Full Text] [PDF]

				D. L. Ornstein and J. R. Rigas Taxotere: Clinical Trials in Non-Small Cell Lung Cancer Oncologist, April 1, 1998; 3(2): 86 - 93. [Abstract] [Full Text]